Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOPHYLLIN vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is 7-9 hours in healthy adults; increases to 20-30 hours in congestive heart failure, cirrhosis, or severe COPD; decreases to 3-5 hours in smokers (tobacco or marijuana) due to enzyme induction.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; hepatic metabolism accounts for 90%, with metabolites excreted in urine. Biliary/fecal excretion is negligible (<2%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to albumin; binding is nonlinear and decreases at higher serum concentrations.
65% bound to albumin
0.4-0.7 L/kg, approximating total body water (0.45 L/kg in adults). Vd is increased in neonates (0.6 L/kg) and decreased in obesity (0.3-0.4 L/kg) due to reduced lean body mass.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 90-100%; Oral sustained-release: 80-100% relative to immediate-release; Rectal solution: 100%; Rectal suppository: 60-80% (erratic).
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
For GFR <30 m L/min: reduce maintenance dose by 50%; consider monitoring serum concentrations.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 75%; Child-Pugh Class C: avoid use or use with extreme caution with 80% dose reduction.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
IV loading dose: 5-7 mg/kg over 20-30 minutes; maintenance IV infusion: 0.5-1 mg/kg/hour for ages 1-9 years, 0.4-0.7 mg/kg/hour for ages 9-16 years; oral: 10-20 mg/kg/day in divided doses every 6-8 hours, maximum 600 mg/day.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients: reduce loading dose to 4-5 mg/kg; maintenance dose 0.2-0.3 mg/kg/hour IV or 200-400 mg/day oral; monitor serum theophylline levels closely due to decreased clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None explicitly required by FDA, but use with caution due to narrow therapeutic index and potential for severe toxicity.
No FDA black box warning.
Narrow therapeutic index; monitor serum concentrations regularly. Risk of arrhythmias, seizures, and gastrointestinal bleeding. Use lower doses in heart failure, liver disease, and elderly. Avoid abrupt discontinuation due to withdrawal symptoms.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to xanthines, active seizure disorders, severe arrhythmias, and uncontrolled hyperthyroidism.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing theophylline levels. Limit caffeine intake (coffee, tea, cola) as it may add to theophylline's stimulant effects. High-fat meals may delay absorption; take consistently with or without food.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third trimesters: no known adverse fetal effects. However, use only if clearly needed.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Excreted into breast milk; M/P ratio approximately 0.6-0.8. Relative infant dose is low (<10% of maternal weight-adjusted dose). No reports of adverse effects in breastfed infants. Caution advised in preterm or ill infants.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy reduces theophylline clearance by 30-50%, especially in the third trimester. Dose may need reduction by up to 50% to maintain therapeutic levels. Monitor levels closely and adjust accordingly. Postpartum clearance rapidly returns to prepregnancy levels, requiring dose increase to avoid subtherapeutic levels.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
LANOPHYLLIN is a fixed-dose combination of lansoprazole, a proton pump inhibitor, and theophylline, a methylxanthine bronchodilator. Monitor serum theophylline levels due to lansoprazole's potential to inhibit CYP1A2, increasing theophylline toxicity risk. Avoid in patients with hepatic impairment or acute asthma exacerbation. Taper theophylline to prevent withdrawal seizures.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take this medication exactly as prescribed, usually once daily in the morning.,Swallow the capsule whole; do not crush or chew.,Avoid drinking alcohol or consuming grapefruit products while on this medication.,Report symptoms like nausea, vomiting, palpitations, or seizures immediately.,Do not stop abruptly; consult your doctor for gradual dose reduction.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOPHYLLIN vs AEROLATE, answered by our medical review team.
LANOPHYLLIN is a Bronchodilator that works by Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOPHYLLIN and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOPHYLLIN is: 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOPHYLLIN and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOPHYLLIN is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.